Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study

Benoit Rousseau, Arezki K. Boukerma,Julie Henriques, Romain Cohen,Olivier Lucidarme, Christophe Borg,Christophe Tournigand, Stefano Kim,Jean-Baptiste Bachet, Thibault Mazard,Christophe Louvet, Benoist Chibaudel,Dewi Vernerey, Thierry Andre,Anne Hulin

European Journal of Cancer（2022）

引用 1|浏览15

暂无评分

摘要

-Therapeutic monitoring of regorafenib in metastatic colorectal cancer is feasible.-We define a safe range of residual concentration regorafenib + M-2+M-5.-This range translates into a survival benefit and decreased serious adverse events.-Only one-third of the patients are within range at C1 D14.-Therapeutic monitoring of regorafenib may help to optimise its dose.

查看译文

关键词

Regorafenib,Chemorefractory metastatic colorectal cancer,M-2,M-5,Survival,Pharmacokinetic,Pharmacological monitoring

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要